• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·UK·Consumer Cyclical·REL.L
Held by 2 Gurus
Share

RELX Plc Stocks

£ 2607Last Updated 31.07.2026

Issuer Rating

6/7
Performance

Average

Risk

Low

Recommendation

Buy

Market Cap

£ 61.38B

£ 2607
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Steven Cohen

Portfolio Weight (%)

0.0%

Change

-0.00%

Fund

Point72 Asset Management, L.P.

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

-0.00%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Steven CohenPoint72 Asset Management, L.P.0.0%-0.00%
Kenneth GriffinCITADEL ADVISORS LLC0.0%-0.00%

Latest news

27.01.2026 18:10

UBS shares top European picks ahead of earnings season, incl. three small caps

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

RELX PLC is a global enterprise that furnishes professional and business clients with sophisticated information-based analytics and decision-making instruments across North America, Europe, and other international markets. Its operations are organized into four primary divisions: Risk; Scientific, Technical & Medical; Legal; and Exhibitions. The Risk segment delivers advanced analytical and decision-support tools by integrating public and industry-specific content with cutting-edge technology and algorithms, empowering clients to evaluate and predict risks effectively. Through its Scientific, Technical & Medical segment, the company provides essential information and analytical insights, enabling institutions and professionals to foster scientific progress and enhance healthcare worldwide. The Legal segment offers comprehensive legal, regulatory, and commercial information alongside analytics, assisting customers in making well-informed decisions and boosting their operational efficiency. Furthermore, the Exhibitions segment manages a dynamic events portfolio, combining in-person interactions with data-driven and digital solutions to help attendees understand markets, source products, and finalize business transactions. Founded in 1903 and headquartered in London, United Kingdom, the organization operated as Reed Elsevier PLC before adopting the RELX PLC name in July 2015.

Company Valuation

Overvalued
2/7

Based on key historical and expected multiples, the stock is overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBITDA, r

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of REL.L is 3288 and suggests 26.1% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

03.08.2026 17:55

AstraZeneca shares plummeted following news of a mega-deal with Bristol Myers

03.08.2026 17:38

A Motley Fool analyst called it a "safe bet" in the cannabis market

03.08.2026 16:54

"Valuations Are Reasonable Again": What Analysts Are Advising After the Sell-Off of Former Favorites

03.08.2026 16:10

After the July sell-off: Has the golden age for chipmakers come to an end?

03.08.2026 15:20

Warsh suggested that the Fed might reduce the number of meetings on interest rates

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026